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ABSTRACT 
Objective: The objective of this study was to evaluate the cytotoxic potential of A3AR agonist (ABMECA) against human lung cancer cell line A549 
by using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay.  
Methods: Adenocarcinoma cell line A549 was used to assess MTT based cells viability. In vitro cytotoxic activity was evaluated for 3 different 
concentration of doxorubicin and A3AR by MTT cytotoxicity assay. Cytotoxicity assay carried out for 3 consecutive days that involves culturing cells 
into Dulbecco’s MEM medium modified with 10% FBS for 24 h then treatment with different dose of standard and test drug with incubation period 
of 24 h followed by treatment with MTT for estimation of cytotoxicity and finally, optical density (OD) was measured at 570-630 nm.  
Results: Different concentration of doxorubicin (1, 5, 10 µM) and ABMECA (10-6M, 10-5M and 10-4M) shown dose-dependent cytotoxicity. There was 
a significant decrease (p<0.05) in cell viability in both doxorubicin and ABMECA concentration in a dose-dependent manner. This study may guide 
further for in vivo evaluation of test drug in the lung cancer model.  
Conclusion: A3 Adenosine Receptor agonist could be potential moiety for the treatment of lung cancer and it would require in vivo study for further research.  
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According to WHO, Cancer is a leading cause of death worldwide, 
accounting for an estimated 9.6 million deaths in 2018. The most 
common cancer is Lung cancer (2.09 million cases) and death due to 
Lung cancer expected to 1.76 million. Lung cancer is the leading cause of 
cancer death across the world. Although science shown dramatic 
advancement in the field of cancer biology, occurrence and mortality of 
lung cancer shown continuously rise globally. The worldwide incidence 
and mortality from various cancers in the year 2008 have been 
estimated for more than 100 countries under the GLOBOCAN series that 
later published by the International Agency for Research on Cancer. 
According to this report, the global prevalence of lung cancer is 12.7% 
(1.61 million). According to ICMR Cancer Registry, a total of 41,000 lung 
cancer cases would have been diagnosed as per data from the July 2002. 
The survival rate of lung cancer improved only 14% in contrast to the 
five-year survival of 52% in comparison to other cancers [1, 2]. All these 
data indicating sharply rising the incidence of cancer through worldwide.  
Different therapeutic approaches for lung cancer have been 
evaluated, including the treatment with a cytotoxic agent called as 
chemotherapy, radiation and biologic therapies also called as 
Immunotherapy, both as monotherapy and in combination for its 
synergism and reducing toxicities [3], but it is not effective. Recently, 
adenosine receptors have been emerged as novel cancer cell-specific 
targets [4]. Adenosine is a purine nucleoside found within the 
interstitial fluid of tumor at high concentrations compare to normal 
cell. By affecting stimulation or inhibition of adenylyl cyclase, agonist 
of various receptor scans modulates tumor growth by interacting 
with all four G-protein-coupled adenosine receptors (AR) designated 
as A1, A2A, A2B and A3. The availability of specific agonists and 
antagonists enabling the evaluation of these ligands as an 
immunomodulator and anticancer agents. Interestingly, up 
regulation of A3AR had been found in various tumor cells. This 
finding may suggest that the specific AR may work as a biological 
marker. If we could target this with specific ligands, it may be 
leading to cell growth inhibition in cancer [5]. 
A3AR agonists exert a differential effect on normal and tumor cells. 
Compare to normal cells in which the A3AR agonists induce the 
production of growth factors, apoptosis and tumor growth inhibition 
takes place in tumor cells [5]. There is much evidence support the 
link in between cancer and inflammation, and A3AR had been 
identified as a link for the same [6]. Arrests of cell cycle and 
induction of apoptosis are main pharmacological action that result of 
activation of A3AR by its agonist which ultimately inhibits the 
proliferation of human lung cancer cells. A3AR have also been found 
to modulate TNF-α and VEGF. Moreover, the modulation of Akt-
mediated signaling pathway is involved in the anti-proliferative 
effect [6, 7]. 
In this study, we have evaluated the cytotoxicity of a novel molecule 
ABMECA and doxorubicin by MTT assay. MTT assay working based 
on the principle of that yellow MTT (tetrazole) is reduced to purple 
formazan in the mitochondria of living cells. Reduction reaction 
depends on the functioning of the mitochondrial enzyme that can be 
directly correlated to living cells. The formed crystal of formazan 
later dissolved in suitable solvent like Dimethyl sulfoxide. Then 
absorbance of this colored solution can be quantified with a 
spectrophotometer at a wavelength range between 500 and 600 nm. 
After that to determine the cytotoxicity of test drug, the amount of 
formazan produced by untreated control cells can be compared. The 
cytotoxicity of the test drug can be inferred, through the production 
of a dose-response curve and comparing significance in between 
group. An increase in dead cell number results in an increase in the 
amount of MTT formazan formed that can be directly correlated by 
an increase in absorbance at specific wavelength [8]. There is certain 
limitation of MTT assay to determine cytotoxicity, like depends on 
physiological state of cells results, may be varies, mitochondrial 
dehydrogenase activity varies in different cell types, it may be 
possible that exposure to MTT and its conversion of formazan 
crystals cause cytotoxicity and abnormal alteration to cellular 
morphology take place. Also, it is less sensitive compares to 
fluorescent or luminescent assays in case of cells with low 
proliferation rate or with metabolically poor active and few chemical 
compounds like coenzyme A, polyphenols and vitamin A interfere 
with the reduction of MTT to formazan [9]. 
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A549 (adenocarcinoma) cell line was obtained from the National 
Centre for Cell Science (NCCS), Pune. A549 cells are cultured in 
Dulbecco’s MEM medium modified with 10% FBS. Maintained in a 
humidified atmosphere of 5 % CO2 in air at 37 °C in cell culture lab. 
All the chemicals purchased from good quality manufacturing 
companies. It involves ABMECA (1 mg) from Sigma Aldrich, 
doxorubicin (10 mg vial) from Pfizer, Phosphated buffered Saline 
from HIMEDIA, DMEM from HIMEDIA, dimethyl sulfoxide (DMSO) 
from HIMEDIA, MTT-salt from HIMEDIA.  
MTT was weighed with proper handling precaution and dissolved in 
sterile phosphate-buffered saline in Eppendorf tube with aluminum 
foil covering at 5 mg/ml and cannot stored for more than 3 w in the 
dark at 4’ C temperature. Whole assay the procedure was divided in 
to three parts. On day 1, separation and counting of cells from 
incubation flask was carried out. After counting 50000 cells were 
transferred to each well with fresh media. Than the plate was 
incubated for next 24 hrs. Then on day 2, drug solutions were 
applied to the each well according to the previously decided protocol 
along with fresh media. Than the plate was incubated for next 24 
hrs. At last on day 3, 40μl of MTT solution (5 mg/ml) was 
administered to each well. Then the plate was incubated for 3-4 h at 
37ᵒC temperature. After incubation, the media was removed. After 
removal of media 200 μl of DMSO (Hi Media) solution was added to 
each well. Again, the plate was incubated at room temperature for 
15-30 min. Finally, OD was taken at 570-630 nm [10]. 
After deriving absorbance of control, standard, test and blank, the 
absorbance reading of the blank must be deducted from control and 
all samples. Then, Absorbance readings from test samples divided by 
those of the control and multiplication with 100, give a percentage of 
cell viability or proliferation. If absorbance value is greater than the 
control, then it indicates cell proliferation and if lower than control 
values it suggests cytotoxicity or inhibition of proliferation. 
 
The results were expressed as mean±SEM A value of p<0.05 was 
considered statistically significant. 
In this study different concentration of doxorubicin (1, 5, 10 µM) and 
ABMECA (10-6M, 10-5M and 10-4M) were used to determine its 
potential cytotoxicity on A549 Human lung Cancer Cell line by MTT 
assay (fig. 1). Result indicated that a decline in absorbance at 540 
nm in the cells treated with increasing concentration of the both 
doxorubicin and ABMECA in comparison to the control cells that 
suggest cytotoxicity of both chemicals. Doxorubicin and ABMECA 
both shown significance difference (p<0.05) compared to normal 
control (fig. 2). 
 
 
Fig. 1: (A) Normal cells, (B) Cells after MTT application
 
 
Fig. 2: Shows the % cell viability after drug treatment in vitro by performing cell cytotoxicity assay. The graphs show a significant decrease in cell 
viability in doxorubicin-3 concentration (p<0.05). There is a significant decrease in cell viability in A3AR AGONIST-3 concentration (p<0.05) 
 
 
Fig. 3(A): (A) Photomicrograph of MTT assay of the cells treated with doxorubicin (1μM) (B) Photomicrograph of MTT assay of the cells 
treated with doxorubicin (5μM) (C) Photomicrograph of MTT assay of the cells treated with doxorubicin (10μM) 
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Fig. 3(B): (A) Photomicrograph of MTT assay of the cells treated with ABMECA (10-6M) (B) Photomicrograph of MTT assay of the cells 
treated ABMECA (10-5M) (C) Photomicrograph of MTT assay of the cells treated with ABMECA (10-4M) 
 
Cell line study provides good initiative in the beginning of drug 
discovery to check the cytotoxicity assay of unknown lead molecules. 
MTT assay used to assess the cytotoxic potential of most of the anti-
cancer chemicals in vitro. The principle behind the assay is that 
mitochondrial reduction of MTT tetrazolium salt to formazan of living 
cells by succinate dehydrogenase. Then, compound dissolved in DMSO 
for colorimetric measurement. There are many drawbacks link to MTT 
assay that cannot overlook and need to consider while preparing for in 
vivo study [12]. Reduction of MTT tetrazolium not only restricted to 
mitochondria but also takes place on plasma membrane, in the 
cytoplasm, in lysosomes, phase of cell cycle and gets affected by pH. It 
has been observed that MTT assay is significantly influenced by many 
compounds that disturb cell metabolism by elevating NADPH level, 
lactate dehydrogenase activity, which leads to false-negative result [8, 
10]. In vitro, results indicate cytotoxicity and anti-proliferative activity 
of Adenosine receptor agonist ABMECA that work as backbone to 
evaluate its activity for in vivo animal models. AR are therapeutic 
targets of many disorders like cardiovascular, immunological, and 
inflammatory and sleep [13]. Although MMT based cytotoxicity study 
depends on disturbance of basic function of cell line, further 
investigation of test drug in in vivo can be done to translate this result 
in living organisms. Cell line study definitely shows the path for anti-
cancer drug discovery and development [14]. During this research, we 
found that ABMECA has shown more potent cytotoxic activity 
compared to doxorubicin (fig. 3). Both molecules have shown 
significant difference compare to cell line without any treatment. The 
hidden potential of test drug was evaluated in the future with the 
properly designed Pre-clinical study.  
ACKNOWLEDGMENT 
The authors gratefully acknowledge the financial support provided by 
Ramanbhai Patel College of Pharmacy, Charusat University, Changa 
AUTHORS CONTRIBUTIONS 
All the author have contributed equally 
CONFLICT OF INTERESTS 
All the authors of this manuscript declared no conflict of interest 
REFERENCES 
1. Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. 
Cancer incidence and mortality worldwide: IARC Cancer Base 
No. 11:GLOBOCAN 2012 v1.0;2012. Available from: 
http://globocan.iarc.fr. [Last accessed on 21 Jun 2018] 
2. NICPR. Cancer Statistics; 2017. Available from: 
http://www.cancerindia.org.in/statistics [Last accessed on 21 
Jun 2018]. 
3. Merighi S, Simioni C, Gessi S, Varani K, Mirandola P, Tabrizi MA, 
et al. A2B and A3 adenosine receptors modulate vascular 
endothelial growth factor and interleukin-8 expression in 
human melanoma cells treated with etoposide and 
doxorubicin. Neoplasia (New York, NY) 2009;11:1064-73.  
4. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, 
et al. A glance at adenosine receptors: a novel target for 
antitumor therapy. Pharmacol Ther 2003;100:31-48. 
5. Fishman P, Bar Yehuda S, Synowitz M, Powell JD, Klotz KN, 
Gessi S, et al. Adenosine receptors and cancer. Hand Exp 
Pharmacol 2009;193:399-441. 
6. Sacchetto V. The a3 adenosine receptor: a link between 
inflammation and cancer. Pubblicazionidello IUSS 2010;3:1-
149.  
7. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. 
Inhibition of TNF-alpha expression by adenosine: role of A3 
adenosine receptors. J Immunol 1996;156:3435-42. 
8. https://blog.quartzy.com/2017/05/01/cell-viability-assays-
mtt-protocol. [Last accessed on 05 Apr 2018] 
9. Hwa Yeon Jo. The unreliability of MTT assay in the cytotoxic 
test of primary cultured glioblastoma cells. Exp Neurobiol 
2015;24:235-45. 
10. Ashutosh Bahuguna, Imran Khan, Vivek K Bajpai, Sun Chul 
Kang. MTT assay to evaluate the cytotoxic potential of a drug. 
Bangladesh J Pharmacol 2017;12:115-8.  
11. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR. 
Tetrazolium-based assays for cellular viability: a critical 
examination of selected parameters affecting formazan 
production. Cancer Res 1991;1:2515–20. 
12. Wang P, Henning SM, Heber D. Limitations of MTT and MTS-
based assays for measurement of antiproliferative activity of 
green tea polyphenols. PLoS One 2010;5:e10202. 
13. Kenneth A Jacobson, Zhan Guo Gao. Adenosine receptors as 
therapeutic targets. Nat Rev Drug Discovery 2006;5:247–64  
14. Habeela J, Mohan MR. In vitro cytotoxic and apoptosis study of 
chemical constituents from clerodendrum phlomidis leaf on 
mcf-7 and a549 cancer cell lines. Asian J Pharm Clin Res 
2018;11:299-304.
 
